Standout Papers

Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective 2024 202650
  1. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective (2024)
    Paul Gougis, Floriane Jochum et al. EClinicalMedicine

Immediate Impact

24 standout
Sub-graph 1 of 12

Citing Papers

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
1 intermediate paper

Works of Baptiste Abbar being referenced

Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
2022
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
2019

Author Peers

Author Last Decade Papers Cites
Baptiste Abbar 259 133 55 25 351
Samer Tabchi 209 135 64 23 315
Sarah Yentz 246 115 45 30 385
Mingjia Li 202 91 55 29 303
Fadi Braiteh 153 80 55 19 375
Mitchell S. von Itzstein 205 96 37 32 317
Valeria Stati 176 95 58 25 303
Lianfang Pu 186 58 58 20 313
Gary W. Jean 230 92 77 14 364
Aru Wisaksono Sudoyo 221 184 66 33 367
Meinrad Mannhart 299 131 44 19 401

All Works

Loading papers...

Rankless by CCL
2026